Combining molecular targeted therapies

Pivot, Xavier; Bedairia, Nadia; Thiery-Vuillemin, A.; Espié, Marc; Marty, Michel

doi:10.1097/cad.0b013e328345ffa4

Cited by 7 publications

(5 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MTT are as yet untested in pituitary tumors including carcinomas, and the absence of a clear mutated target makes identification of optimal agents preclinically challenging. However, as in other tumors, many of these kinase pathways are activated in pituitary tumors, providing some rationale for evaluation, although preclinical activity of MTT has been poorly predictive of antitumor activity and tolerability (79).…”

Section: Future Therapeutic Optionsmentioning

confidence: 99%

Pituitary Carcinoma: Difficult Diagnosis and Treatment

Heaney

2011

The Journal of Clinical Endocrinology &Amp; Metabolism

185

155

View full text Add to dashboard Cite

Although pituitary carcinoma remains difficult to diagnose and treat, recent developments have led to improved outcomes in selected cases. With broader use of molecular markers, efforts to modify current histopathological criteria for pituitary carcinoma diagnosis may now be possible. This would assist earlier diagnosis and, in combination with targeted therapies, potentially improve long-term survival.

show abstract

Section: Future Therapeutic Optionsmentioning

confidence: 99%

Pituitary Carcinoma: Difficult Diagnosis and Treatment

Heaney

2011

The Journal of Clinical Endocrinology &Amp; Metabolism

185

155

View full text Add to dashboard Cite

show abstract

“…29 In this instance, the therapeutic benefit of antiangiogenic therapy seemed to be manifested primarily as a reduced total and functional micro-vascular density and a marked increase in necrosis. 29 The clinical promise of this strategy was demonstrated in a phase I study 30 in 26 patients with breast cancer who were treated with the combination of trastuzumab, lapatinib and the VEGF-A inhibitor bevacizumab, with six of the 10 patients who had brain metastasis achieving prolonged stable disease lasting 6 months or more.…”

Section: The Biology Of Brain Metastasesmentioning

confidence: 99%

Current approaches to the treatment of metastatic brain tumours

et al. 2014

View full text Add to dashboard Cite

Metastatic tumours involving the brain overshadow primary brain neoplasms in frequency and are an important complication in the overall management of many cancers. Importantly, advances are being made in understanding the molecular biology underlying the initial development and eventual proliferation of brain metastases. Surgery and radiation remain the cornerstones of the therapy for symptomatic lesions; however, image-based guidance is improving surgical technique to maximize the preservation of normal tissue, while more sophisticated approaches to radiation therapy are being used to minimize the long-standing concerns over the toxicity of whole-brain radiation protocols used in the past. Furthermore, the burgeoning knowledge of tumour biology has facilitated the entry of systemically administered therapies into the clinic. Responses to these targeted interventions have ranged from substantial toxicity with no control of disease to periods of useful tumour control with no decrement in performance status of the treated individual. This experience enables recognition of the limits of targeted therapy, but has also informed methods to optimize this approach. This Review focuses on the clinically relevant molecular biology of brain metastases, and summarizes the current applications of these data to imaging, surgery, radiation therapy, cytotoxic chemotherapy and targeted therapy.

show abstract

“…HER2 [13], [14] and EGFR [15], [16] and molecular therapies for other growth factor receptors are still investigational. In addition to being therapeutic targets, growth factor receptors might be useful for molecular imaging [17]–[19].…”

Section: Introductionmentioning

confidence: 99%

Differential Expression of Growth Factor Receptors and Membrane-Bound Tumor Markers for Imaging in Male and Female Breast Cancer

et al. 2013

View full text Add to dashboard Cite

IntroductionMale breast cancer accounts for 0.5–1% of all breast cancers and is generally diagnosed at higher stage than female breast cancers and therefore might benefit from earlier detection and targeted therapy. Except for HER2 and EGFR, little is known about expression of growth factor receptors in male breast cancer. We therefore investigated expression profiles of growth factor receptors and membrane-bound tumor markers in male breast cancer and gynecomastia, in comparison with female breast cancer.MethodsTissue microarrays containing 133 male breast cancer and 32 gynecomastia cases were stained by immunohistochemistry for a panel of membrane-bound targets and compared with data on 266 female breast cancers.ResultsGrowth factor receptors were variably expressed in 4.5% (MET) up to 38.5% (IGF1-R) of male breast cancers. Compared to female breast cancer, IGF1-R and carbonic anhydrase 12 (CAXII) were more frequently and CD44v6, MET and FGFR2 less frequently expressed in male breast cancer. Expression of EGFR, HER2, CAIX, and GLUT1 was not significantly different between male and female breast cancer. Further, 48.1% of male breast cancers expressed at least one and 18.0% expressed multiple growth factor receptors. Since individual membrane receptors are expressed in only half of male breast cancers, a panel of membrane markers will be required for molecular imaging strategies to reach sensitivity. A potential panel of markers for molecular imaging, consisting of EGFR, IGF1-R, FGFR2, CD44v6, CAXII, GLUT1, and CD44v6 was positive in 77% of male breast cancers, comparable to female breast cancers.ConclusionsExpression patterns of growth factor receptors and hypoxia membrane proteins in male breast cancer are different from female breast cancer. For molecular imaging strategies, a putative panel consisting of markers for EGFR, IGF1-R, FGFR2, GLUT1, CAXII, CD44v6 was positive in 77% of cases and might be considered for development of molecular tracers for male breast cancer.

show abstract

Combining molecular targeted therapies

Cited by 7 publications

References 72 publications

Pituitary Carcinoma: Difficult Diagnosis and Treatment

Pituitary Carcinoma: Difficult Diagnosis and Treatment

Current approaches to the treatment of metastatic brain tumours

Differential Expression of Growth Factor Receptors and Membrane-Bound Tumor Markers for Imaging in Male and Female Breast Cancer

Contact Info

Product

Resources

About